PACS Group, Inc. (PACS)
| Market Cap | 6.77B +267.8% |
| Revenue (ttm) | 5.55B +15.2% |
| Net Income | 269.17M +103.5% |
| EPS | 1.71 +107.4% |
| Shares Out | 158.34M |
| PE Ratio | 25.00 |
| Forward PE | 16.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,828 |
| Open | 44.34 |
| Previous Close | 44.24 |
| Day's Range | 42.75 - 44.61 |
| 52-Week Range | 7.50 - 49.49 |
| Beta | -0.08 |
| Analysts | Strong Buy |
| Price Target | 59.20 (+38.48%) |
| Earnings Date | Aug 4, 2026 |
About PACS
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. The company engages in the acquisition, ownership, and leasing of health care-related properties. PACS Group, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Financial Performance
In 2025, PACS Group's revenue was $5.29 billion, an increase of 29.32% compared to the previous year's $4.09 billion. Earnings were $191.54 million, an increase of 243.51%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PACS stock is "Strong Buy." The 12-month stock price target is $59.2, which is an increase of 38.48% from the latest price.
News
Pacs Group price target raised to $57 from $48 at Oppenheimer
Oppenheimer raised the firm’s price target on Pacs Group (PACS) to $57 from $48 and keeps an Outperform rating on the shares. The firm notes the company reported strong results…
Pacs Group price target raised to $60 from $57 at UBS
UBS analyst AJ Rice raised the firm’s price target on Pacs Group (PACS) to $60 from $57 and keeps a Buy rating on the shares.
Pacs Group price target raised to $62 from $52 at Truist
Truist analyst David MacDonald raised the firm’s price target on Pacs Group (PACS) to $62 from $52 and keeps a Buy rating on the shares. Pacs delivered another strong quarter…
Pacs Group price target raised to $57 from $52 at RBC Capital
RBC Capital analyst Ben Hendrix raised the firm’s price target on Pacs Group (PACS) to $57 from $52 and keeps an Outperform rating on the shares.
PACS Group Earnings Call Transcript: Q2 2026
Second quarter 2026 saw 9.1% revenue growth and 50% net income increase, with margin expansion driven by occupancy and patient mix improvements. Full-year guidance was raised for both revenue and adjusted EBITDA, reflecting strong core trends and disciplined acquisitions.
PACS Group Quarterly report: Q2 2026
PACS Group has published its Q2 2026 quarterly earnings report on August 5, 2026.
PACS Group Earnings release: Q2 2026
PACS Group released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
PACS Group Slides: Q2 2026
PACS Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Pacs Group reports Q2 adjusted EPS 63c, consensus 56c
Reports Q2 revenue $1.43B, consensus $1.41B. The company said, “Our second quarter results reflect the continued strength of the PACS platform and the exceptional execution of our local leadership tea...
PACS Group, Inc. Reports Second Quarter 2026 Results
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United State...
PACS Group Schedules Second Quarter 2026 Earnings Release and Conference Call
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) announced today that it intends to report its financial results for the second quarter ended June 30, 2026, on ...
Pacs Group price target raised to $57 from $50 at UBS
UBS raised the firm’s price target on Pacs Group (PACS) to $57 from $50 and keeps a Buy rating on the shares.
PACS Group to Acquire Operations of 34 Facilities Across Texas, Montana, New Mexico, North Dakota, South Dakota, and Utah
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) announced today that subsidiaries of the Company have entered into a definitive agreement to acquire the operations of 34 skilled nursing...
Varist Announces AI-Scale Malware Detection for Healthcare and Medical Imaging
REYKJAVIK, Iceland--(BUSINESS WIRE)--Varist today introduced its DICOM Detection Engine™, a specialized system designed to safeguard healthcare communications networks, electronic health records (EHR)...
PACS Group Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation approval. All proposals passed, with final vote results to be published in a Form 8-K. No questions were submitted by stockholders.
Pacs Group price target raised to $52 from $50 at Truist
Truist raised the firm’s price target on Pacs Group (PACS) to $52 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect…
Pacs Group price target raised to $48 from $42 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Pacs Group (PACS) to $48 from $42 and keeps an Outperform rating on the shares after the company reported earnings.
PACS Group Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth and a 75% rise in Adjusted EBITDA, driven by strong occupancy, skilled mix, and operational execution. Full-year Adjusted EBITDA guidance was raised by $50 million, with robust liquidity and a new $250 million share repurchase plan.
PACS Group Quarterly report: Q1 2026
PACS Group has published its Q1 2026 quarterly earnings report on May 12, 2026.
PACS Group Earnings release: Q1 2026
PACS Group released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
PACS Group Slides: Q1 2026
PACS Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Pacs Group reports Q1 EPS 50c, consensus 41c
Reports Q1 revenue $1.42B, consensus $1.36B. Reports Q1 adjusted EBITDA $170.4M vs. $97.6M last year.
Pacs Group raises FY26 adjusted EBITDA view to $605M-$625M from $555M-$575M
16:32 EDT Pacs Group (PACS) raises FY26 adjusted EBITDA view to $605M-$625M from $555M-$575M